Hepatitis C genotype 4: A report on resistance‐associated substitutions in <scp>NS3</scp>, <scp>NS5A,</scp> and <scp>NS5B</scp> genes

Fadl, Nahla; Salem, Tamer Z.

doi:10.1002/rmv.2120

Cited by 3 publications

(1 citation statement)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another remarkable compound for this aspect is rosmarinic acid, whose distance was 2.116 Å/2.179 Å RMSD (Figure 5). The non-structural protein NS5B is the core of HCV replication [67]. It is an RNA-dependent RNA polymerase (RdRp) that, when interacting with other proteins, promotes the formation of the viral RNA replication complex [68].…”

Section: Molecular Docking Analysismentioning

confidence: 99%

In Silico Potential Antiviral Activity of Polyphenols From Plants Used in Traditional Medicine in La Libertad Región, Peru

Valdiviezo-Campos,

Rodriguez Aredo,

Ruiz-Reyes

et al. 2023

Preprint

View full text Add to dashboard Cite

Traditional medicine is one of the main bases for studying and discovering natural sources of phytometabolites with antiviral properties. This research aims to demonstrate that the medicinal plants used as a treatment of viral diseases in the La Libertad region have, in fact, antiviral ac-tivity. The study evaluated the ethnobotany of the 8 most widely used medicinal plants in the region (Azadirachta indica A. Juss. “paraíso”, Caesalpinia spinosa (Molina) Kuntze “tara”, Citrus limon (L.) Osbeck “limón”, Clinopodium pulchellum (Kunth) Govaerts “panizara”, Cordia lutea Lam. “overo”, Ocimum basilicum L. “albahaca”, Schinus molle L. “molle”, and Taraxacum campylodes G.E. Haglund “diente de león”). The phytometabolites responsible for the antiviral activity were identified by LC-MS and evaluated in silico against the viral proteins NS2B/NS3 (DENV-2), NS5B (HCV), and ICP27 (HSV-1) using molecular docking in Autodock Vina and UCSF Chimera. The presence of five polyphenols (chlorogenic acid, gallic acid, caffeic acid, rosmarinic acid, and rutin) was found and, in the in silico test, the antiviral activity of chlorogenic acid stood out against DENV-2 and HCV, rutin against HCV and HSV-1, rosmarinic acid against DENV-2 and HCV. Therefore, it is verified that the medicinal plants studied have antiviral activity, which supports their use in traditional medicine

show abstract

Section: Molecular Docking Analysismentioning

confidence: 99%

In Silico Potential Antiviral Activity of Polyphenols From Plants Used in Traditional Medicine in La Libertad Región, Peru

Valdiviezo-Campos,

Rodriguez Aredo,

Ruiz-Reyes

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective

Zhou

Zhang

Zhou

et al. 2022

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges

Shahid

Jabeen

2023

Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives

View full text Add to dashboard Cite

Oral interferon-free DAAs (IFN-free DAAs) have proven their clinical and therapeutic worth in real-life situations by achieving higher sustained virologic response rates (SVRs >90%) in treated individuals. After their recommendations to be administered to hepatitis C-infected populations in 2017 more than 5 million hepatitis C-infected individuals have been treated across the world and the overall health care burden of active hepatitis C comorbidities and mortalities have been declined from 130 million hepatitis C patients to approximately 71 million. Despite these great achievements in hepatitis C therapeutics, certain patient-oriented, clinical, and societal challenges are still prevailing to accept IFN-free DAAs on the large scale clinical, hospital, and primary health care settings in low and middle-income countries as well as even in developed nations. High therapy costs, treatment access and monitoring, co infection status of certain vulnerable hepatitis C infected populations, racial disparity, pre-, and post-therapeutic monitoring, and long-term follow-ups are potential barriers to consensually implementing uniform treatment algorithms and accessibility to DAAs regimens worldwide. Furthermore, recurrence of hepatitis C infection, reactivation risks of co-infections (e.g., HCV/HIV, HCV/HBV or HCV/CKD), minefield risks of hepatocellular carcinoma (HCC) rebound, and surveillance of hepatitis C liver transplant recipients which are on treatment with IFN-free DAAs also limit the administration of these regimens to every hepatitis C infected individual. In this book chapter, we will explore all these real-world challenges and will discuss/suggest the strategies to coup them in clinical, hospital, and community settings to improve the cascades of care and scale-up HCV cure.

show abstract

Hepatitis C genotype 4: A report on resistance‐associated substitutions in NS3, NS5A, and NS5B genes

Cited by 3 publications

References 93 publications

In Silico Potential Antiviral Activity of Polyphenols From Plants Used in Traditional Medicine in La Libertad Región, Peru

In Silico Potential Antiviral Activity of Polyphenols From Plants Used in Traditional Medicine in La Libertad Región, Peru

Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective

Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges

Contact Info

Product

Resources

About